Quantedge Capital Pte Ltd Purchases New Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Quantedge Capital Pte Ltd acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 75,600 shares of the company's stock, valued at approximately $3,366,000. Omnicell makes up about 1.2% of Quantedge Capital Pte Ltd's investment portfolio, making the stock its 23rd biggest position. Quantedge Capital Pte Ltd owned 0.16% of Omnicell at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Franklin Resources Inc. grew its position in shares of Omnicell by 49.9% during the third quarter. Franklin Resources Inc. now owns 30,807 shares of the company's stock worth $1,316,000 after buying an additional 10,260 shares in the last quarter. Accurate Wealth Management LLC raised its holdings in Omnicell by 33.4% in the fourth quarter. Accurate Wealth Management LLC now owns 28,369 shares of the company's stock valued at $1,199,000 after acquiring an additional 7,109 shares in the last quarter. Arkadios Wealth Advisors boosted its stake in Omnicell by 27.6% during the 4th quarter. Arkadios Wealth Advisors now owns 43,454 shares of the company's stock valued at $1,935,000 after acquiring an additional 9,404 shares during the last quarter. SG Americas Securities LLC grew its holdings in Omnicell by 56.5% during the 4th quarter. SG Americas Securities LLC now owns 39,359 shares of the company's stock worth $1,752,000 after acquiring an additional 14,202 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in Omnicell by 6.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company's stock worth $14,232,000 after acquiring an additional 20,031 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on OMCL. Wells Fargo & Company reduced their price target on shares of Omnicell from $38.00 to $31.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Benchmark cut their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. decreased their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Finally, StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a report on Saturday, May 3rd. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $45.83.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $28.00 on Wednesday. The stock has a market capitalization of $1.31 billion, a P/E ratio of 103.71, a P/E/G ratio of 7.53 and a beta of 0.78. The firm's 50-day moving average price is $31.89 and its two-hundred day moving average price is $39.80. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business's revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $0.03 EPS. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.